CSE:MDMA - Post Discussion
Post by
Betteryear2 on Mar 20, 2024 11:12am
Patent Allowance Granted C.MDMA
TORONTO, March 20, 2024 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is thrilled to announce that allowance has been granted for the Composition of Matter of its PharmAla-1 (P-1) molecule by the US Patent and Trademark Office (USPTO). P-1 is an enantiomerically pure composition of ((R)-2-[(2H-1,3-benzodioxol-5-yl)methyl]pyrrolidine. Patent Allowance Granted for P-1 Molecule by US Patent and (globenewswire.com)
Be the first to comment on this post